SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of PolarityTE, Inc. (COOL)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of PolarityTE, Inc. (COOL) |
| [25-June-2018] |
NEW YORK, June 25, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PolarityTE, Inc. ("PolarityTE" or the "Company") (NASDAQ: COOL). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/cool.
The investigation concerns whether PolarityTE and certain of its officers and/or directors have violated federal securities laws. On June 25, 2018, Citron Research released a report calling PolarityTE a "fraud," and accused the Company of failing to disclose that its key technology has been rejected by the United States Patent and Trademark Office, just days before the Company's offering. Following this news, PolarityTE's stock dropped during intraday trading on June 25, 2018. If you are aware of any facts relating to this investigation, or purchased PolarityTE shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/cool. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes. Contact:
SOURCE Bronstein, Gewirtz & Grossman, LLC | ||
Company Codes: NASDAQ-SMALL:COOL |
View original content with multimedia:© 2018 PR Newswire. All Rights Reserved.
#content-news .main-news{color:#737373;font-size:14px;line-height:inherit;text-align:inherit}Aptinyx (Nasdaq: APTX) Reports Positive, Statistically Significant, Top-line Data From Phase 2 Study of NYX-783 in Patients With Post-Traumatic Stress Disorder (PTSD)
